Table 1.

Patients characteristics

Patients no.	Age years	Gender	Diagnosis	Treatment	Initial serum BNP level	Mean serum BNP level during medication	Serum BNP level after medication	Clinical manifestation of HF	Initial weight	Weight during medication	Initial BP	BP during medication
1	22	Female	AML	AML201	0	109.94	38.11	No	31	32	128/86	135/89
2	34	Male	ALL	VDLP	21.08	79.28	26.23	No	58	57.5	128/71	134/80
3	23	Male	AML	AML201	0	35.91	10.5	No	65	65	120/71	128/75
4	29	Female	AML	AML201	5.35	131.10	41.64	No	47	47	105/65	110/70
5	36	Female	AML	AML201	0	207.76	12.04	No	48	48.5	103/75	110/78
6	49	Female	AML	AML201	20.33	63.81	7.74	No	57	56.5	113/74	121/82
7	22	Female	ALL	E2993	21.46	73.07	31.4	No	46	46.8	109/73	115/78
8	35	Female	AML	AML201	0	129.23	19.61	No	45.5	45	133/80	135/81
9	58	Male	AML	AML201	99.05	359.28	168.6	Yes	69	75	140/80	146/85
10	53	Female	CML	AML201	17.58	33.37	37.27	No	40	40	130/81	136/85
11	59	Female	AML	AML201	24.5	173.98	148.57	No	53	52	117/67	120/69
12	30	Female	ALL	VDLP	22.68	105.66	60.59	No	49	48.5	105/66	109/70
13	20	Male	ALL	E2993	4.93	44.29	35.89	No	74	74	118/72	124/75
14	19	Male	ALL	E2993	55.21	84.77	30.12	No	80	80	134/81	138/89
15	34	Female	AML	AML201	5.26	109.91	109.05	No	53	54	109/71	116/79
16	30	Male	ALL	E2993	8.72	19.08	9.56	No	71	70	122/75	128/78
17	32	Female	AML relapse	Cladribine+Aclarubicin	2.52	95.91	46.79	No	39	39	112/69	120/74
18	30	Male	ALL	E2993	27.4	35.68	33.33	No	75	74.5	135/79	138/84
19	53	Female	AML	Cladribine+Aclarubicin+Cytarabine	35.28	502.47	78.61	Yes	70	74	134/79	139/85
20	40	Female	AML	AML201	2	127.12	6.37	No	50	49.5	113/77	119/84
21	25	Female	AML	AML201	77.29	213.42	103.4	No	44	45	99/63	108/72
22	42	Male	AML	AML201	27.26	181.29	68.78	No	58	58	99/66	110/74
23	29	Female	ALL	E2993	4.11	899.71	84.36	Yes	55	57	128/82	136/88
24	66	Male	ALL	E2993	42.4	1343.97	466.14	Yes	64	67	133/79	137/88